Latest Recruitment News

Ceretas Limited posted a $1.63 million net loss for FY26 on $1.28 million revenue from government grants, advancing its clinical-stage Alzheimer’s ultrasound platform. The company completed an $8 million IPO in July to fund pivotal trials and device development.

PeopleIN Limited reversed its earnings decline in FY26, driven by a 74.8% surge in its Engineering, Trades and Labour division amid Queensland’s booming infrastructure projects. The company’s sharper portfolio focus and strengthened balance sheet set the stage for further growth.

The Agency Group Australia Ltd (ASX:AU1) reported a 21% jump in Gross Commission Income to $151.6 million for FY26, alongside a 56% reduction in net loss. The company expanded its agent network and property management portfolio, navigating a softening housing market with operational discipline.

PYC Therapeutics strengthened its financial footing with a $600 million capital raise and made notable clinical progress across four RNA therapeutic programs targeting genetic diseases.

Paradigm Biopharmaceuticals has surpassed its Phase 3 enrolment target for Zilosul®, secured over A$21 million in capital, and pivots towards clinical evidence generation with major data readouts expected.

OpenLearning Limited accelerated its SaaS revenue growth to a record $3.27 million in HY2026, boosting gross margin to 63% and cutting its EBITDA loss by over a quarter amid expanding multi-year institutional contracts.

Resonance Health (ASX: RHT) reported a profitable turnaround in FY26, driven by growth across its imaging software, clinical trial services, and site network businesses.

Patrys has cleared a key regulatory hurdle with Human Research Ethics Committee approval for its Phase 1A clinical trial of RLS-2202, aiming to start dosing healthy volunteers this quarter.

Percheron Therapeutics has partnered with Vanderbilt Health to initiate a clinical trial testing HMBD-002 in combination with standard treatments for high-risk acute myeloid leukaemia and myelodysplastic syndrome, targeting a recruitment start in late 2026.

Syntara Limited’s FY2026 results show a 7.9% revenue decline and a 13.6% increase in net loss amid significant clinical progress, including FDA backing for its lead drug amsulostat and a successful $8.8 million capital raise.

Winton Land’s governance is under strain after independent directors Steven Joyce and Guy Fergusson resigned citing conflicts with the majority shareholder. The board must urgently appoint new independent directors to maintain NZX compliance and avoid potential trading suspension.

Clarity Pharmaceuticals reported a 67% increase in net loss to $107.2 million for FY26, driven by higher R&D spending, while advancing multiple Phase III trials and expanding manufacturing capacity ahead of commercialisation.